Why AbCellera Biologics (ABCL) Is Back on Investor Radar

Investor attention on AbCellera Biologics (ABCL) is building ahead of its Q1 earnings call, with many watching for upcoming Phase 1 and Phase 2 data on antibody candidates ABCL635 and ABCL575.

The stock has drawn fresh interest as the company advances 19 molecules into clinical development across internal and partnered programs, alongside recent insider purchases, institutional participation, and a reaffirmed positive analyst view of its antibody discovery platform.

AbCellera's recent momentum is hard to ignore, with a 31.94% 7 day share price return, 48.67% 30 day share price return and 150.75% 1 year total shareholder return. At the same time, the 5 year total shareholder return remains sharply negative, which points to renewed interest ahead of upcoming clinical updates and the Q1 earnings call.

If this kind of rebound has your attention, it could be a good moment to see what else is moving in healthcare AI and antibody discovery by checking out 33 healthcare AI stocks

With the stock up sharply in recent months yet still trading well below analyst targets, the real question now is whether AbCellera is still underappreciated or if the market is already pricing in future growth.

Most Popular Narrative: 49% Undervalued

Against a last close of $5.04, the most followed narrative pegs AbCellera's fair value at $9.83, setting up a wide gap between market price and model.

The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is described as likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities. Financial backing with over $630 million in liquidity and additional funding commitments is cited as providing AbCellera with the resources to support long-term pipeline development, which the narrative links to potential future earnings through successful commercialization of their clinical candidates.

Want to see what kind of revenue curve and profit margin shift the narrative suggests could justify that uplift, under a 7% discount rate and a premium future earnings multiple? The full narrative lays out those assumptions clearly, along with how fast the top line would need to compound and how much operating leverage would need to show up to support that $9.83 figure.

Result: Fair Value of $9.83 (UNDERVALUED)

However, there are still real pressure points, including widening net losses and heavy R&D spend, that could challenge the thesis if clinical or partnered programs stall.

Another View: Price Versus Sales Tells a Very Different Story

While the narrative model points to a fair value of $9.83, the simple P/S check paints a tougher picture. AbCellera trades on a P/S of 20.3x, compared with 4x for peers and a fair ratio of just 0.3x, which implies meaningful valuation risk if sentiment cools.

For a closer look at how this pricing gap stacks up against peers, and what the numbers imply if the market moves toward that fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed on the story so far and unsure how the balance tips between risk and reward? Act quickly by reviewing the numbers, reading both sides of the debate, and weighing the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If AbCellera has you thinking more broadly about where to put fresh capital to work, do not stop here. Widen your opportunity set with a few targeted screens.

• Target potential bargains early in their journey by checking out 22 elite penny stocks with strong financials that pair smaller market caps with stronger fundamentals than many expect.
• Zero in on quality at a reasonable price by reviewing the 47 high quality undervalued stocks that combine solid cash generation with balance sheets designed to handle bumps in the road.
• Prioritize resilience first by scanning 74 resilient stocks with low risk scores that show lower risk scores, so you are not only chasing upside but also paying attention to capital preservation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.